Background: In obese patients undergoing sleeve gastrectomy, the blood and fatty-tissue concentrations of cefazolin required for adequate antibiotic prophylaxis are uncertain. Methods: This was a single centre prospective study in obese (Group A: 40 BMI 50 kg m
Editor's key points
Staphylococcus aureus is a common cause of surgical site infection. For cefazolin, the minimum inhibitory concentration is 4 mg g À1 tissue.
Guidelines commonly recommend prophylactic administration of cefazolin 4 g i.v. in moderately and severely obese patients. Subcutaneous tissue concentrations at the end of bariatric surgery in obese patients were above the minimum inhibitory concentration at this dose.
Obesity has increased substantially worldwide over the past two decades, affecting an estimated 36.9% of men and 38% of women across the globe in 2013. 1 Bariatric surgery is the only efficient long-term treatment for obesity. 2 Obesity is a risk factor for surgical site infection (SSI), which is a source of morbidity and increased healthcare costs. 3, 4 In thoracic surgery, the rate of superficial SSI was 2.2% and deep SSI was 1.8%, and obesity was an independent factor of SSI. 5 In a monocentric study regarding general surgery, the rate of SSI was up to 10% in obese patients. 6 In sleeve gastrectomy, the SSI rate ranges between 2.3 and 4.6%, 7 depending on postoperative complications. Antibiotic prophylaxis reduces the occurrence of SSI. 8, 9 In obese patients, antibiotic pharmacokinetics are likely to be impaired, as renal and hepatic clearance and volume of distribution are significantly modified. 10 These modifications could affect the pharmacokinetics of antibiotics and, therefore, impair their efficacy profile in SSI prophylaxis. Some authors have also reported that cefazolin distribution was impaired in subcutaneous tissues along with an increased volume of distribution. 11 The American Society of HealthSystem Pharmacists, the Infectious Diseases Society of America, the Surgical Infection Society, and the Society for Healthcare Epidemiology of America currently recommend cefazolin 2 g before surgery, and a second dose after 4 h, in patients weighing more than 80 kg, and 3 g before surgery followed by a second dose after 4 h in patients weighing more than 120 kg. 12 The French Society of Anesthesia and Critical Care Medicine [Soci et e Franç aise d'Anesth esie et de R eanimation (SFAR)] recommends cefazolin 4 g before surgery followed by a second dose of 2 g after 4 h. 13 The discrepancies concerning cefazolin administration during bariatric surgery highlight the controversies that have emerged in the current literature. Moreover, although data in the current literature suggest reduced cefazolin subcutaneous tissue concentrations, data regarding subcutaneous fatty-tissue concentrations in severely obese patients are lacking. We studied the blood and fatty-tissue pharmacokinetics of cefazolin in sleeve gastrectomy surgery in moderately to severely obese patients after an initial 4 g injection, as recommended by the guidelines of the SFAR. 13 The primary outcome was to study subcutaneous fatty-tissue concentration of cefazolin at the end of surgery, and to compare this concentration to Staphylococcus aureus minimum inhibitory concentration (MIC), which is one of the main pathogens causing SSI.
Methods
This was a single centre observational study conducted at Nantes Teaching Hospital, a reference centre in bariatric surgery, between May 1, 2012 and March 1, 2015. The study was registered as NCT01537380. This study was approved by the ethics committee at Tours Teaching Hospital (no. BRD 11/6-R).
Patients eligible to participate in this study received information and gave their written consent.
Inclusion criteria
Patients scheduled for sleeve gastrectomy surgery were eligible if they were !18 yr old, with a BMI !40 and 65 kg m À2 , and they also had to have French health insurance cover.
Exclusion criteria
Patients were excluded in case of pregnancy, mild to moderate chronic renal failure (calculated creatinine clearance 65 ml min À1 with the Modification of Diet in Renal Disease (MDRD) formula), and hypersensitivity to cephalosporin.
Study protocol
In the operating room, an initial 4 g dose of cefazolin was administered intravenously according to the guidelines of the SFAR. 13 The general anaesthesia protocol combined the i.v.
administration of propofol (3e5 mg kg À1 ) and remifentanil (2e4 mg kg À1 ). A cisatracurium bolus 0.5 mg kg À1 was set up before intubation and was administered by continuous perfusion during surgery (0.3e0.5 mg kg À1 h À1 ). Drug dosages were adapted to ideal body weight. After initiation of the general anaesthesia, a perfusion line devoted to the pharmacological dosages was inserted in the patient's contralateral arm.
The same surgeon performed all surgical procedures (E.L.). The surgeon performed subcutaneous fatty tissue and perigastric tissue biopsy just after surgical incision and at the end of the procedure just before skin closure. Four fatty-tissue samples were taken per patient. Free cefazolin plasma concentrations during surgery in each group were also studied according to the following time frame: T 0 (surgical incision); 15, 30, 60 min post-incision; and surgical closure. The patients received cefazolin during surgery. Antibiotics were discontinued at the end of surgery.
Determination of free cefazolin plasma concentration
Free-plasma cefazolin concentrations were determined according to a previously validated method.
14 The plasma samples were thawed and incubated at 37 C for 20 min. 
Determination of cefazolin concentration in subcutaneous and perigastric fatty tissues
Tissue samples were rinsed with saline solution and were blotted to remove residual blood. Blood contamination was checked by visual examination of each sample. After removing residual blood from the fatty tissue, tissue fractions were weighed, sonicated, and centrifuged at 13 000 g for 5 min. Five hundred microlitres of subnatant was mixed with 500 ml acetonitrile and centrifuged at 13 000 g for 5 min.
Eight hundred microlitres of the supernatant was added to dichloromethane (4 ml). The tubes were shaken horizontally for 10 min and centrifuged at 1800 g for 5 min at þ4 C. Fifty microlitres of the upper aqueous layer was injected into the high-performance-liquid-chromatography system in the chromatographic conditions described previously. In our study, the cefazolin tissue concentration in the fatty tissue was considered as the total cefazolin concentration.
The limits of quantitation were 1 mg litre À1 in the plasma and 1 mg g À1 in the fatty tissue. The methods were accurate (inter-day and intra-day inaccuracy <15%) and showed good precision (inter-day and intra-day imprecision <15%).
Data collection
Patient-characteristic data were recorded: age, gender, BMI, body surface area, baseline creatinine, and creatinine clearance calculated with the MDRD formula. During surgery, the time of cefazolin injection and blood and fatty-tissue sample collection was recorded. Perioperative blood loss and vascular expansion were recorded. We then recorded the occurrence of SSI in the 30 days after surgery. 15 
Primary outcome
We divided the population into two groups: the first group (Group A) was that of patients with 40 BMI 50 kg m À2 , whilst the second group (Group B) was that of patients with severe obesity (50< BMI 65 kg m À2 ). The primary outcome of our study was subcutaneous fatty-tissue cefazolin concentrations (mg g À1 ) at the end of surgery (T end ) in both groups. To determine the efficacy of prophylactic free-plasma cefazolin, currently the time of cefazolin concentration above the MIC between the opening and closure of the wound is used as the pharmacokinetic/pharmacodynamic index. According to this index, cefazolin fatty concentration at closure (end of surgery) was finally used. The concentrations were compared with the target tissue concentrations (4 mg g À1 in adipose tissue). The target is based on the MIC 90 (MIC at which 90% of tested strains were inhibited) of methicillin-sensitive S. aureus isolates, the most common pathogens in wound infections. The MIC 90 is usually 2 mg litre À1 ; 16 however, higher values (4 mg litre À1 ) have been described in previous studies after cefazolin administration for the prevention of surgical infection.
11,17
Secondary outcomes
The perigastric fatty-tissue cefazolin concentrations at incision and at the end of surgery in both groups were also evaluated. The areas under the cefazolin concentration curve in subcutaneous tissue and perigastric fatty-tissue time curve (AUC) were determined using the trapezoidal rule during the time between incision and wound closure. The free-plasma cefazolin concentrations were compared with the MIC 90 for S. aureus. Finally, we evaluated the incidence of SSI and the occurrence of cefazolin side-effects. SSI 18 occurs in bariatric surgery as a skin abscess and could theoretically occur on the site of gastrectomy, which is why we recorded subcutaneous and perigastric fatty-tissue infections. (Table 2 ). There were no differences in cefazolin concentration in subcutaneous and perigastric fatty tissue between the two groups ( Table 2 ). There was no difference in the AUC for subcutaneous and perigastric fatty-tissue cefazolin concentrations (Table 2 ). During surgery, the free-plasma cefazolin concentrations exceeded the MIC 90 of the S. aureus resistance breakpoint (Fig. 1) . The free-plasma cefazolin concentrations were significantly higher in Group A than in Group B (P<0.0001) (Fig. 1 ). There were no differences regarding the intraoperative management between Group A and Group B (Table 3) . Finally, no SSI and no side-effects from cefazolin were recorded.
Statistical analysis

Discussion
This study discusses the largest cohort of moderately to severely obese patients, in which the blood and fatty-tissue concentrations of cefazolin were studied. A single injection of cefazolin 4 g i.v. appears to provide high cefazolin concentrations in fatty tissues and plasma in moderately obese patients undergoing a moderate-duration surgery. Several important conclusions can be drawn from our study. Firstly, there was no significant difference in perigastric fatty-tissue cefazolin concentrations between moderately to severely obese patients, even if the free-plasma cefazolin concentrations for the active form of cefazolin were lower in severely obese patients in comparison with obese patients. Although there is no obvious explanation for this finding, low albumin plasma concentrations could induce an increase in the volume of distribution, 11 leading to lower cefazolin plasma concentrations. Nevertheless, in both groups, the concentration of free plasma was drastically higher than the S. aureus resistance breakpoint. Previous studies have mentioned that cefazolin administration significantly decreased SSI after bariatric surgery. 9 However, the exact dosage to be administered in moderately and severely obese patients remains controversial. Edmiston and colleagues 20 suggested that the administration of cefazolin 2 g may be insufficient in patients with BMI !50 kg m À2 during bypass surgery, and this finding was also corroborated in severely obese patients after Caesarean delivery. 19 Conversely, others suggested that a 2 g injection should be enough to provide adequate antibiotic coverage, provided the surgery lasts less than 5 h. 21 In a retrospective cohort study, obese and non-obese patients displayed similar rates of SSI with cefazolin 2 g coverage. 22 On the other hand, during Caesarean delivery, the administration of cefazolin 2 g did not provide adequate adipose concentrations, especially in women with a BMI >40 kg m À2 , and a 3 g injection could therefore be proposed in this setting. 23 Recent results pointed out that a cefazolin 2 g injection would provide adequate coverage in obese patients, 24 but too few severely obese patients were included to verify this finding in this subgroup of patients. These results explain the discrepancies between North American 12 and French guidelines. 13 The dosages of cefazolin used in this specific setting are, therefore, highly variable and range from 2 to 4 g. We, therefore, provide data in a large cohort of patients with a BMI of between 40 and 65 kg m À2 .
Some authors 25 have pointed out that a pharmacokinetic study involves evaluation of antibiotic dosages in tissues, and interstitial space fluid or muscles. Owing to modifications of blood volume, general and local blood flow, or renal clearance because of obesity or surgery, 26e28 the diffusion of antibiotics could be altered, rendering their efficacy on pathogens unknown. In our study, the concentration of cefazolin in the interstitial space fluid was not studied. The only technique allowing measurement of free cefazolin concentrations in the interstitial fluid is microdialysis, which remains the gold standard. 29 We did not perform a microdialysis pharmacokinetic analysis, which has nonetheless several drawbacks: it requires a time-consuming calibration and a skilled operator, and usually deals with subcutaneous fatty tissue 11 and not perigastric fatty tissue. Because of the number of patients and the time in the operating theatre, microdialysis was not possible. The concentration of cefazolin in the fatty tissue cannot be considered as free (i.e. active) cefazolin concentration at the site of infection, which is the main limit of our study. The samples were obtained by grinding up fatty tissues. As a consequence, the dilution of cefazolin induced by mixing intracellular and extracellular fluids results in the underestimation of cefazolin concentration, which is usually located in the extracellular compartment. 30 Thus, the cefazolin concentration measured in fatty tissues is only a surrogate value of active cefazolin concentration. More specifically, we did not study muscles and interstitial space concentrations to ascertain that a cefazolin 4 g administration is sufficient, especially in severely obese patients. This is a clear limitation, but the active concentration of cefazolin in tissues should be above this target with this dosage. We, therefore, believe that a preoperative cefazolin 4 g administration, in accordance with the French recommendations, 13 should provide an adequate antibiotic coverage in obese patients undergoing a moderate duration of surgery, considering a 4 mg g À1 tissue concentration
target. Recent studies suggest that continuous infusion can increase the achievement of target plasma concentrations with even lower total doses of cefazolin in surgical patients. 31 The pharmacokinetic target was cefazolin concentrations above the MIC of pathogens involved in SSI throughout the surgery. The cefazolin concentrations exceeded the MIC 90 of S. aureus resistance breakpoint for nearly all patients in subcutaneous fatty tissue and all patients in the plasma. For a tissue target of 2 mg g À1 instead of 4 mg g À1 , based on the MIC 90 2 mg litre À1 usually observed, 23 100% of patients in Groups A and B had subcutaneous fatty-tissue cefazolin concentrations above this target at the end of the surgery. Other pathogens involved in SSI, such as Staphylococcus epidermidis or the Enterobacteriaceae may exhibit a higher MIC to cefazolin. 16 In this context, the administration of cefazolin 4 g could be insufficient. Nevertheless, in our study, no SSI was recorded and no cefazolin-related side-effects noted. Our data suggest that an administration of cefazolin 4 g provides high antibiotic tissue concentrations for Methicillin susceptible Staphylococcus Aureus, Gram-negative bacilli with low MIC, in short-duration surgery, and non-severely obese patients.
There is a sampling bias in our study, but was limited, as one surgeon performed all procedures. Extrapolation to longer surgery and simulation of a different dosage regimen scheme allowing higher coverage to more resistant strains should be performed by calculating the population pharmacokinetic model mean from these data. We included 79 patients in Group A as per the power calculation, but we did not achieve our goal in Group B. However, this remains the largest cohort to date in obese and severely obese patients.
Although we do not provide cefazolin extracellular concentrations, this study suggests that cefazolin 4 g administered before operation provides a high fatty-tissue antibiotic concentration, for short-duration surgery, in moderately obese patients. In severely obese patients, longer surgery, or 
Funding
University Hospital of Nantes (grant number BRD 11/6-R) .
